Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.36 |
| ▸ | SPHK1 | Q9NYA1 | 3/20 | 0.34 |
| ▸ | SPHK2 | Q9NRA0 | 2/20 | 0.34 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.32 |
| ▸ | BCHE | P06276 | 1/20 | 0.31 |
| ▸ | ACHE | P22303 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | ADH1B | P00325 | 1/20 | 0.30 |
| ▸ | ADH1C | P00326 | 1/20 | 0.30 |
| ▸ | ADH1A | P07327 | 1/20 | 0.30 |
| ▸ | ADH4 | P08319 | 1/20 | 0.30 |
| ▸ | ADH7 | P40394 | 1/20 | 0.30 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.30 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23545040 | 0.84 | OPRM1 (0.33) | SPHK1SPHK2OPRM1BCHEACHE | |
| SCHEMBL25960290 | 0.84 | OPRM1 (0.33) | SPHK1SPHK2OPRM1BCHEACHE | |
| SCHEMBL21026098 | 0.84 | OPRM1 (0.33) | SPHK1SPHK2OPRM1BCHEACHE | |
| SCHEMBL25017716 | 0.78 | GAA (0.36) | GPR84SPHK1SPHK2 | |
| SCHEMBL10192262 | 0.77 | MAPT (0.32) | — | |
| SCHEMBL22930733 | 0.75 | GPR119 (0.32) | SPHK1SPHK2 | |
| SCHEMBL22930730 | 0.72 | POLB (0.37) | — | |
| SCHEMBL22604328 | 0.72 | MAPT (0.35) | SPHK1 | |
| SCHEMBL19592432 | 0.71 | MAPT (0.34) | SPHK1 | |
| SCHEMBL24176213 | 0.70 | NR2F2 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230286933-A1 | 2,5-ARYL-THIAZOLE ANALOGS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | SOUTHERN RES INST (US) | 2023-09-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230286933-A1 | 2,5-ARYL-THIAZOLE ANALOGS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | SMN1; SMN2, TDP2, TDP1 | GPR84 2435/4885SPHK1 3870/4885SPHK2 3145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.